- AZD-7762
-
- $32.00 / 1mg
-
2025-11-10
- CAS:860352-01-8
- Min. Order:
- Purity: 99.17%
- Supply Ability: 10g
|
| | 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide Basic information |
| Product Name: | 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide | | Synonyms: | 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide;5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide;AZD 7762;White solid;1-(2-((S)-piperidin-3-ylcarbamoyl)-5-(3-fluorophenyl)thiophen-3-yl)urea;5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide AZD 7762;AZD 7762
5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide;(S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide | | CAS: | 860352-01-8 | | MF: | C17H19FN4O2S | | MW: | 362.42 | | EINECS: | | | Product Categories: | api;Inhibitors | | Mol File: | 860352-01-8.mol | ![3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide Structure](CAS/GIF/860352-01-8.gif) |
| | 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide Chemical Properties |
| Boiling point | 547.6±50.0 °C(Predicted) | | density | 1.38 | | storage temp. | -20° | | solubility | Soluble in DMSO (up to at least 25 mg/ml). | | form | solid | | pka | 9.06±0.20(Predicted) | | color | Yellow or brown | | Stability: | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
| | 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide Usage And Synthesis |
| Description | Actively proliferating cells experience blocks at certain checkpoints in the cell cycle when DNA damage is detected. These checkpoints allow for DNA damage repair before further cell cycle progression. Targeting signaling pathways to selectively inhibit repair at these checkpoints in tumor cells is of considerable interest to cancer therapeutics. AZD 7762 selectively inhibits the activity of checkpoint kinases (Chk) 1 and Chk2 (IC50s = 5 nM) by competitively and reversibly binding their respective ATP-binding sites (Ki = 3.6 nM for Chk1). AZD 7762 abrogates DNA damage-induced S and G2 checkpoints with an EC50 value of 10 nM and potentiates the efficacy of DNA-damage repair prohibitive agents, gemcitabine and topotecan, both in vitro and in various tumor xenografts by modulating downstream checkpoint pathway proteins. | | Uses | AZD 7762 is studied as an cancer therapeutic agent due to its selective inhibitory activities towards checkpoint kinases, chk1 and chk2 by reversibly binding their respective ATP-binding sites within
tumor cells. Recent research has also indicated AZD 7762 to possess enhancing effects towards other chk1 inhibitor lethality in glioblastoma cells. | | Definition | ChEBI: 3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide is an aromatic amide and a member of thiophenes. | | in vivo | In the rat H460-DNp53 xenograft study, AZD-7762 (AZD7762) potentiates the antitumor activity of NSC 613327 in a dose-dependent manner by a decrease in %T/C with increasing dose (48% and 32%, 10 and 20 mg/kg AZD-7762, respectively). In the mouse xenograft study in combination with CPT-11, SW620 established tumors are treated with vehicle, CPT-11 alone, AZD-7762 alone, or AZD-7762 in combination with CPT-11. AZD-7762 dosed alone shows insignificant antitumor activity, whereas CPT-11 alone displays striking and significant activity (%T/C with increasing dose is 9 and 1, respectively ). In combination with AZD-7762, %T/C increases significantly to -66% and -67%, respectively[1]. AZD7762 combination with CX-5461 induces cancer cell death of Tp53-null (Tp53-/-) Eμ-Myc lymphoma cells in vitro and in vivo[2]. | | IC 50 | Chk1: 5 nM (IC50); Chk2: 5 nM (IC50) | | References | [1] SONYA D ZABLUDOFF. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.[J]. Molecular Cancer Therapeutics, 2008, 7 9: 2955-2966. DOI:10.1158/1535-7163.mct-08-0492
[2] JAMES B MITCHELL. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.[J]. Clinical Cancer Research, 2010, 16 7: 2076-2084. DOI:10.1158/1078-0432.ccr-09-3277
[3] MEREDITH A MORGAN. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.[J]. Cancer research, 2010, 70 12: 4972-4981. DOI:10.1158/0008-5472.can-09-3573
[4] HU LEI. Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells[J]. Leukemia research, 2018, 64: Pages 17-23. DOI:10.1016/j.leukres.2017.11.007
[5] SYED AHMAD John E S Gary L Johnson. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity[J]. Biochemical and biophysical research communications, 2015, 463 4: Pages 888-893. DOI:10.1016/j.bbrc.2015.06.029
[6] YOUNG HWAN PARK . Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn[J]. Biochemical pharmacology, 2018, 154: Pages 270-277. DOI:10.1016/j.bcp.2018.05.012 |
| | 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide Preparation Products And Raw materials |
|